Artesunate

1 paper3 findings

PubChem 6917864 ChEBI 63918 MeSH D000077332

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funder: Harbin Medical University

Animals1

Outcomes

Oxidative stress and ROS signalling

downin mouse cells1

1 study

Artesunate decreases oxidative stress and ROS signalling in mouse cells.
“ART treatment rescued the aged phenotypes and ameliorated the ROS accumulation of H2O2-induced aged BMSCs in vitro.”
CellsH2O2-induced
Artesunate reverses BMSC senescence and ameliorates osteoporosis by upregulating NSD2
European journal of pharmacology5 Dec 2025

More on Oxidative stress and ROS signalling

Cellular senescence

downin mice1

1 study

Artesunate inhibits cellular senescence in mice.
“Intragastric administration of ART effectively alleviated age-related bone loss and BMSC senescence in SOP mice.”
AnimalsSOPintragastric administrationbone marrow
Artesunate reverses BMSC senescence and ameliorates osteoporosis by upregulating NSD2
European journal of pharmacology5 Dec 2025

Latest

1 in 12 months

European Journal of Pharmacology8 Dec

Artesunate reverses BMSC senescence and ameliorates osteoporosis by upregulating NSD2

Experiments in miceBones and joints

Paper

Artesunate

Outcomes

Latest

Artesunate reverses BMSC senescence and ameliorates osteoporosis by upregulating NSD2

Related